Clear Search

Showing 5 results for “Houssiau F”.

November 2023

EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update

Ann Rheum Dis 2023; 2023-224762 DOI: 10.1136/ard-2023-224762 Epub ahead of print

 The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.

more…

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis

Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322

This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.

more…

March 2022

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

Ann Rheum Dis. 2022;81(4):496–506 doi: 10.1136/annrheumdis-2021-221478

Despite not meeting the primary endpoint, this Phase II trial of anifrolumab in patients with active lupus nephritis (LN) demonstrates that anifrolumab IR is associated with numerical improvements over placebo across endpoints – including complete renal response – in patients with active LN.

more…

October 2021

Two-Year, Randomised, Controlled Trial of Belimumab in Lupus Nephritis

N Engl J Med. 2020;383(12):1117–28.

LN occurs in 25–60% of patients with SLE. However, patients with LN are often excluded from clinical trials of SLE therapies.

more…